Table 8.
Cost of reversal agents–based on an 80-kilogram patient.
| Generic Drug | Trade Name | Dose | Approximate Cost |
|---|---|---|---|
| Phytonadione | Vitamin K | 10 mg IV | $395.00A |
| FFP | N/A | 4 units is usual minimum | $1000B ($250 each) |
| 4-Factor PCC | Kcentra | 25–50 units/kg | $2,540 to $5,080B |
| Activated PCC | FEIBA | 25 units/kg | $5,400B |
| Idarucizumab | Praxbind | 5 grams | $3,600C |
| Andexanet (Low Dose) | Andexxa | 400 mg bolus + 480 mg infusion | $24,750** |
| Andexanet (High Dose)* | Andexxa | 800 mg bolus + 960 mg infusion | $49,500 |
PCC, prothrombin complex concentrate; FEIBA, factor VIII inhibitor bypassing activity; IV, intravenous; units/kg; units per kilogram; mg, miligram.
High dose rarely used in Annexa-4 study protocol. Predicted to be rarely used in real-life practice.
New technology add-on payment (NTAP) is available with the maximum NTAP reimbursement of $14,062.50, or 50% of the wholesale acquisition cost of the low dose. NTAP is expected to remain in effect for a period of 2–3 years, until the cost of andexanet alfa is included in the recalibration of the diagnosis related group payment rates.
Phytonadione. https://www.drugs.com/price-guide/phytonadione. 2018.
Wexner Medical Center at The Ohio State University pharmacy data. 2019.
Praxbind. http://www.drugs.com/price-guide/praxbind. 2018.